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Implications for Nursing Care 
Multiple Myeloma 




• Bone pain and fractures 
• Fatigue 
• Increased infections 
• Weakness and fatigue 
• Restlessness  
• Confusion 
• Increased thirst 
• Nausea and vomiting 
• Loss of appetite weight 
loss 
• Impaired kidney function 
• Increased or decreased 
urination 
 
     Fatigue is a commonly reported 
symptom of MM often thought to be a 
consequence of anemia (Booker, 
Olson, Pilarski, Noon, and Bahlis, 
2009).  Anemia (mostly normocytic 
normochromic) is seen in 
approximately 75% of patients (Al-
Farsi, 2013) 
      
     In normal physiology mature plasma 
cells make up less than 5% of the bone 
marrow cells. Precursor cells 
plasmablasts and B lymphocytes are 
stimulated by antigens and cytokines then 
migrate to the bone marrow where they 
stop proliferating and begin to 
differentiate to mature plasma cells 
(Mangan, 2005).  The majority of MM is 
preceded by a premalignant disease 
known as monoclonal gammopathy of 
undetermined significance (Manier, Sacco, 
Leleu, Ghobrial, and Roccaro, 2012).  This 
monoclonal neoplasm results in the 
expansion of a single clone of plasma cells 
(Ferreira, 2013). The monoclonal cells 
crowd out healthy cells.  
     Unregulated proliferation of 
monoclonal plasma cells accumulate in 
the marrow which leads to secretion of 
cytokines by the tumor cells.  Here in the 
microenvironment of the bone marrow 
the ability of myeloma to live and 
replicate is thought to occur (Mangan, 
2005).  
     The majority of MM patients eventually 
relapse with all therapeutic options 
currently available (Lawasut, Groen, 
Dhimolea, Richardson, Anderson, and 
Mitsiadesa, 2013). 
     Balance between bone resorption and 
new bone formation is lost in many cases 
of MM, resulting in bone destruction and 
the development of osteolytic lesions 
(Mainer et al., 2012) Bone health is a 
primary concern for MM patients.   
 
  
     Multiple myeloma a rare and largely 
incurable malignant disease the affects 
the plasma cells. (Bilotti, Gleason, 
McNeill, and the International Myeloma 
Foundation Nurse Leadership Board, 
2011).  Understanding the 
pathophysiology of Multiple Myeloma 
(MM) and treatment options in Oncology 
and Hematology  nursing can be difficult. 
It is the goal of this poster to outline the 
pathophysiology, prognosis, treatment 
options available to multiple myeloma 
patients. 
     Multiple myeloma accounts for about 
10% of hematologic malignancies in the 
U.S. (Kuo, Fenves, Mehta, 2011). MM is 
the second most common hematologic 
malignancy with twenty-four thousand 
new MM cases each year (Bianchi, and 
Anderson, 2014 ) 
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     Treatment options include the use of 
monoclonal antibodies against specific 
surface molecules in MM cells (Lawasut et 
al., 2013).  High-dose chemotherapy with 
autologous stem cell transplantation is the 
standard of therapy for patients newly 
diagnosed with multiple myeloma who are 
younger than age 70 or have no 
comorbidities (Tariman, and Estrella, 2005). 
Nursing care occurs in multiple settings. 
“Nurses provide care and education to 
patients at all stages of the multiple myeloma 
(MM) disease continuum, from the 
premalignant stage and diagnosis all the way 
through survivorship and to the end of life.” 
(Nicoletti, 2012)  Patients present to routine 
exams, present to emergency department 
and as inpatients who are newly diagnosed.   
Post diagnosis nursing care involves 
treatment with chemotherapy, care in 
medical surgical settings, survivorship, and 
hospice. 
     Multiple Myeloma diagnosis and 
prognosis is viewed as incurable there 
remains many treatment options based on 
the stage of cancer, age and comorbidities.  
Patient goals should always be considered 
when developing treatment plans and 
discussing options.  Early stages of the 
disease can yield many years of quality life 
with current treatments ranging from 
monoclonal therapies to bone marrow 
transplant. 
For end stage disease patients quality of life 
can be achieved through compassionate 
nursing care delivered by  palliative 
measures and hospice care 
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